Finally, the efficacy of topically applied CoQ10/TPGS micelles was next evaluated in vivo using the well-established Morrison's ocular hypertension model (OHT) (Morrison et al., 1997) and in vivo DARC (Cordeiro et al., 2017) and Brn3a-RGC immunohistochemistry as endpoints (Galvao et al., 2013, Davis et al., 2016b). The gene discussed is POU4F1; the disease is ocular hypertension.